Health Check: Hungary for a new suitor, jilted Mayne finds match second time around

Detailed summary
Fresh from its disastrous marriage attempt last year, Mayne has recommended a fresh offer from Hungary's Gedeon Richter. ... Read More The post Health Check: Hungary for a new…
For better and for worse: while Mayne Pharma looks to have found its perfect match, investors are happy to take the money and run. Pic: Getty Images
In the wake of last year’s aborted takeover of Mayne Pharma (ASX:MYX) by US dermatology group Cosette, Mayne has found a new suitor with a $604 million buyout proposal.
The Hungary-based women’s health group Gedeon Richter is offering $6.40 a share cash for Mayne, by way of a scheme of arrangement.
In February last year Cosette offered $7.40 a share, valuing Mayne at $672m. But bear in mind that Mayne has just agreed to sell its international business to Evaris Pharma, for $55.5m.
The new offer is double Mayne’s closing price last night and a 200% premium to the shares’ March 2026 nadir. That was after the Cosette proposal ended in tears and acrimony.
Founded in Hungary 125 years ago, Richter is a specialty pharmaceutical company, covering around 50 countries.
In addition to women’s health, the company has expertise in neuropsychiatry, biotechnology and general medicines.
Mayne chair professor Bruce Robinson said the offer gave shareholders the opportunity “to realise value at a significant premium to recent trading prices”.
The proposal “recognises the strength” of Mayne’s US women’s health, dermatology and distribution businesses.
Opening of the article, excerpted from Stockhead. To read the rest, open the article on the publisher's site.
MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (stockhead.com.au)




